Robert Mills’ expertise ranges across GMP Operations, Clinical Research, Regulatory Affairs, and Commercial Operations as well as R&D, IT, Product Development, Technical Services, Manufacturing, Engineering, and Quality Assurance. Mr. Mills has a large network of industry relationships, as well as a very strong track record successfully managing businesses, delivering quality products, successfully interacting with the FDA, and generating attractive growth through expanding market share and launching exciting new products. Most recently, he was the President and CEO of Scientific Protein Labs (SPL), the US’s leading manufacturer of heparin and pancreatin, prior to its sale to a Chinese Pharmaceutical company. Before SPL, Mr. Mills was President of Qualitest Pharmaceuticals, a leading manufacturer and distributor of generic pharmaceuticals.
Prior to Qualitest, Bob held senior positions at Columbia Laboratories, Inc., including becoming CEO in 2006, Vice President and General Manager of Watson/Schein’s solid dose division, Vice President of Operations at Alpharma, Inc., and various positions with Sanofi including Director-Plant Operations, Rhone-Poulenc Rorer. His business development experience has led to multiple product acquisitions, joint ventures, and product divestitures. He was recognized as a finalist for Entrepreneur of the Year for New Jersey in 2009 by Ernst and Young. Mr. Mills holds a Bachelor of Science from Grove City College and numerous graduate business credits from Temple University.
Dr. Aaron Fletcher founded and serves as CEO of Bios Research, a financial services firm that provides public equity research in the healthcare space tailored to institutional firms and large family offices. Bios Research provides fundamental healthcare industry research focused on the biotech and med-tech sub-sectors and through this research, Dr. Fletcher has a strong understanding of commercial viability in the marketplace. Dr. Fletcher holds a Doctor of Philosophy in Biochemistry from Colorado State University and serves as a professor at Dallas Baptist University where he teaches Biochemistry, Bioethics, and Cell Biology. Dr. Fletcher has worked as an independent consultant for the biotech/healthcare equity industry for over 10 years.
RA Session II is the President, CEO and Founder of Taysha Gene Therapies. Mr. Session has nearly 20 years’ experience in the life sciences industry, primarily in business development, corporate strategy and financial roles. Previously, he served as Chief Business Officer of the gene therapy subsidiaries of BridgeBio, as well as Senior Vice President of Corporate Strategy and Business Development at AveXis until its $8.7B acquisition by Novartis. Before AveXis, Mr. Session served in various roles for PTC Therapeutics, Inc., most recently as the vice president of commercial development. He previously served in various roles at Reata Pharmaceuticals, Inc., most recently as the senior director of strategic planning and finance. Before Reata Pharmaceuticals, Mr. Session worked at AstraZeneca Pharmaceuticals as senior manager of commercial portfolio and post-deal analytics in the managed markets group. He began his career in the pharmaceutical division of Johnson & Johnson, where he served in several positions including senior financial analyst in the strategic business group.
RA currently serves on the board of directors for Lung Therapeutics, ReCode Therapeutics, and Sandhill Therapeutics.
Mr. Session is a member of the Kauffman Fellows Society. Mr. Session received a Bachelor of Science and a Bachelor of Arts in Finance from the University of North Carolina at Charlotte, a Master of Science in Finance from Texas A&M University-Commerce and a Master of Business Administration from Texas A&M University-Commerce.
Founder and Chief Scientific Officer
Founder and Chief Scientific Officer
Dr. Steven Idell is a clinical investigator who has been continually funded over the past 30 years by the National Institutes of Health for his work in the areas of acute lung injury and pleural diseases. He is a board-certified internist and pulmonologist who has also directed the Intensive Care Units at Temple University Hospital in Philadelphia and The University of Texas Health Science Center at Tyler, Texas. He is now Vice President for Research, a Professor of Medicine and Temple Chair of Pulmonary Fibrosis at UTHSCT and Director of an NIH-sponsored Program Project Grant to study the role of the fibrinolytic system in the pathogenesis of lung and pleural disease. Work from that project led to the development of scuPA as a treatment for pleural loculation and of a peptide-based approach for treating acute lung injury and pulmonary fibrosis.
Dr. Idell also continues to manage patients in the UTHSCT Pulmonary Clinic. He has successfully obtained over $27 million in grant support from agencies including the NIH, The American Heart Association, The American Lung Association, and various foundations. He is the Director of the Texas Lung Injury Institute of UTHCT and has raised nearly $1 million of philanthropic support for lung injury research to develop novel experimental therapeutics from the community, grateful patients and various foundations in East Texas and has received commitment from the NIH RAID and SMARTT programs to perform IND-enabling studies with his lead therapeutic, LTI-01. In addition to his role as CSO, Dr. Idell also serves as Chair of the Scientific Advisory Board and a Member of the Board of Directors.
Chief Executive Officer
Chief Executive Officer
Dr. Brian Windsor has served as President and CEO of Lung Therapeutics since July of 2013. He has spent the last 20 years in the formation and management of life science companies and has led technology development and licensing to major pharmaceutical and biotech companies. Dr. Windsor brings leadership experience in pharmaceutical drug development, and he previously served as President of Enavail, LLC, a specialty pharmaceutical manufacturing company developing unique formulations for superior drug performance. While at Enavail, Dr. Windsor oversaw all aspects of pharmaceutical drug development, including drug selection, regulatory strategy, preclinical and clinical strategy, GMP manufacturing, and strategic partnering for pharma products.
Prior to his role with Enavail, Dr. Windsor directed portfolio company management for Emergent Technologies Inc. (ETI), an early stage technology venture creation and management company. During his tenure at ETI, Dr. Windsor served as Managing Director or President for ten of ETI’s portfolio companies and was involved in the conception, technology licensing, corporate and technical strategic planning, launch, and business development of all of these ventures. Applications areas of these companies span diverse segments within life and material sciences and include pharmaceutical development and manufacturing, drug delivery, and biotechnology.
Prior to joining ETI, he was Founder and Vice President of R&D for Texagen, Inc., a startup focused on genetic and chemical methods for overcoming mechanisms of drug resistance important to medicine and agriculture. At Texagen, he directed outsourced research efforts at university labs and third-party contract research companies, and he interfaced with corporate partners interested in feasibility studies and in-licensing discussions.
He holds a Ph.D. in Molecular Biology from The University of Texas at Austin and is an inventor on multiple patents and patent applications.